IMR Press / EJGO / Volume 24 / Issue 3-4 / pii/2003165

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Hyperthermia in gynecologic cancers

Show Less
1 Department of Obstetrics and Gynecology, Akdeniz University School of Medicine, Antalya, Turkey
Eur. J. Gynaecol. Oncol. 2003, 24(3-4), 282–286;
Published: 10 June 2003

The opinion from most of the current data is that malignant tumors may be more heat sensitive than normal tissues. Hyperther­mia has been tested in both randomized and non-randomized trials in gynecologic cancers, but has not found a place currently, as there is scarce data. As a consequence, adding this tool into the conventional methods of cervical cancer and ovarian cancer treat­ment has not been supported. Hyperthermia modifies the effects of not only ionizing radiation but also a number of chemothera­peutic agents. The use of hyperthermia in cervical cancer is of interest to the radiotherapist, not only because it sensitizes cells to the lethal effects of X-rays but even more because hypoxic cells which are most resistant to X-rays appear to be most sensitive to hyperthermia. Most of the data on the efficacy of intraperitoneal infusion with hyperthermia comes from experimental studies or some phase I/II investigations. Since intraperitoneal chemotherapy is potentiated by hyperthermia in areas which are at high risk for recurrence, further study maybe indicated. The current role for hyperthermia in ovarian cancer remains experimental. Additional trials to test the value of hyperthermia in patients treated with concurrent chemotherapy and radiation are imperative, and good news is expected from the ongoing studies.

Thermal effect
Gynecologic cancer
Back to top